Does empagliflozin improve clinical outcomes in patients with acute decompensated heart failure?
In patients with acute decompensated heart failure, empagliflozin safely increases urinary output and reduces a 60-day composite of worsening HF, rehospitalization, or death, despite no significant effect on dyspnea or NT-proBNP.
In patients with acute HF, treatment with empagliflozin had no effect on change in VAS dyspnoea, diuretic response, NT-proBNP, and length of hospital stay, but was safe, increased urinary output and reduced a combined endpoint of worsening HF, rehospitalization for HF or death at 60 days.
Damman et al. (Tue,) studied this question.